Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Evotec AG    EVT   DE0005664809

EVOTEC AG (EVT)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Sector news Biotechnology & Medical Research - NEC
06/13Sanofi says on track to regain solid position in cancer drugs
RE
06/12GSK says vaccine business president to leave by year-end
RE
06/06Drugmaker Lundbeck to settle U.S. charity probe for $52.6 million
RE
06/01Lilly, Incyte Get FDA OK for Lower-Dose Rheumatoid Arthritis Drug
DJ
05/30Gap in regulating biotech drug copies prompts WHO to step in
RE
05/25Pfizer to pay $23.85 million to settle U.S. co-payment kickback probe
RE
05/18GLAXOSMITHKLINE : Regulators flag possible birth defect link to GSK's HIV drug
RE
05/11Trump's Plan to Cut Drug Prices Leaves Industry Relieved
DJ
05/09Drugmaker GSK rings in more change as CFO heads for exit in 2019
RE
05/08UK biotech firm Autolus joins CAR-T rush with Nasdaq IPO filing
RE
05/03Teva raises 2018 outlook, expects migraine drug approval by year-end
RE
05/03Samsung BioLogics' shares slide again; unit's valuation jump questioned
RE
05/02NOVARTIS : Gets Second FDA Approval for CAR-T Cancer Drug
DJ
05/01GILEAD SCIENCES : Quarterly Results Miss Wall Street Expectations -- Earnings Re..
DJ
04/26GILEAD SCIENCES : The Million Dollar Cancer Treatment No One Knows How to Pay fo..
DJ
04/25Currency and pricing squeeze GSK as new shingles vaccine shines
RE
04/17GE rides gene therapy wave with ready-made viral drug factories
RE
04/06Incyte Shares Tumble After Cancer Drug Fails in Trial With Merck's Keytruda
DJ
03/21Britain's use of copycat biotech drugs takes off while U.S. lags
RE
03/21GlaxoSmithKline prescribes commercial reboot for pharma division
RE
03/21GlaxoSmithKline prescribes commercial reboot for pharma division
RE
03/11REGENERON PHARMACEUTICALS : and Sanofi Plan to Cut Cholesterol Drug Price in Exc..
DJ
03/10REGENERON PHARMACEUTICALS : and Sanofi Plan to Cut Cholesterol Drug Price in Exc..
DJ
03/10Prisons Expand Hepatitis Treatment -- WSJ
DJ
03/09More Prison Inmates Get Access to Hepatitis-C Drugs
DJ
02/22SANGAMO THERAPEUTICS : Surges on Therapy Collaboration Deal with Kite -- Market ..
DJ
02/22Sangamo in $3 billion gene-editing deal with Gilead
RE
02/15French pharma group Ipsen sees more asset purchases, U.S. growth
RE
02/14Bristol-Myers to pay $1.85 billion in cancer deal with Nektar
RE
02/14BRISTOL MYERS SQUIBB : Nektar to Partner on Cancer Therapy
DJ
02/13Drug copies ready to take next bite out of Roche's cancer sales
RE
02/08FTSE slides after BOE meeting as pound pops higher
RE
02/08REGENERON PHARMACEUTICALS : Collaborations Drive Revenue Increase at Regeneron -..
DJ
02/07GlaxoSmithKline sees light at end of Advair tunnel
RE
02/06GILEAD SCIENCES : Reports Quarterly Loss Driven by Tax Charge -- Earnings Review
DJ
01/30Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom
RE
01/22Biotech M&A takes off as Sanofi and Celgene spend $20 billion
RE
01/22New drugs recast $10 billion haemophilia market as Sanofi swoops in
RE
01/12Drugmakers see a pricing blueprint in an $850,000 gene therapy
RE
01/12SPARK'S PRICE FOR LUXTURNA BLINDNESS : Icer
RE
01/08$11 billion biotech binge fuels forecasts of 2018 M&A surge
RE
01/08SANOFI : and Regeneron boost investment in cancer drug cemiplimab
RE
01/07ALNYLAM PHARMACEUTICALS : Sanofi Restructure RNAi Rare-Disease Alliance -- Updat..
DJ
01/07ALNYLAM PHARMACEUTICALS : Sanofi Restructure RNAi Rare-Disease Alliance
DJ
01/05Best week since April for European shares as UK, Swiss indexes hit records
RE
01/02New drug approvals hit 21-year high in 2017
RE
2017U.S. tax cuts mix pleasure and pain for Europe's dollar earners
RE
2017STOCKS TO WATCH : CSX, Aclaris, Alnylam, Rigel
DJ
2017ALNYLAM PHARMACEUTICALS : Stock Rises as FDA Lifts Study Hold
DJ
2017France's Sanofi pins hopes on new drugs after setbacks
RE
1  2  3  4  5  6  7  8  9  10Next
Financials (€)
Sales 2018 351 M
EBIT 2018 46,1 M
Net income 2018 34,2 M
Debt 2018 70,3 M
Yield 2018 -
P/E ratio 2018 61,94
P/E ratio 2019 43,58
EV / Sales 2018 6,32x
EV / Sales 2019 5,76x
Capitalization 2 148 M
Sector Biotechnology & Medical Research - NEC
1st jan.Capitalization (M$)
EVOTEC AG7.81%2 493
CELLTRION, INC.--.--%33 987
IQVIA HOLDINGS INC5.50%21 394
LONZA GROUP3.38%20 341
INCYTE CORPORATION-22.25%15 677
ALNYLAM PHARMACEUTICALS, INC.-15.15%10 836
SEATTLE GENETICS, INC.29.36%10 302
NEKTAR THERAPEUTICS-3.11%9 917
QIAGEN NV6.08%8 575
EXACT SCIENCES CORPORATION23.43%8 354
ALKERMES PLC-8.09%7 798
SAGE THERAPEUTICS INC-10.79%7 672
ICON PLC20.78%7 287
BIO-TECHNE CORP26.64%6 221
PRA HEALTH SCIENCES INC5.41%6 151
IONIS PHARMACEUTICALS INC-5.86%5 845
CHARLES RIVER LABORATORIES INTL. INC4.27%5 618
GALAPAGOS9.14%5 127
UNITED THERAPEUTICS CORPORATION-22.83%5 109
FIBROGEN INC24.16%4 915
SYNEOS HEALTH INC9.52%4 908